Merck & CompanyvsSolventum

MRK and SOLV stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$148.02

Value $366B

+0.18%
MRK's page

SOLV

Solventum Corporation

$89.47

Value $15.5B

+0.44%
SOLV's page

Merck & Company (MRK) has a market value of $366B and Solventum (SOLV) $15.5B. Over the last year, with dividends, MRK moved +64.0% and SOLV +18.3%. The P/E is 149.2 for MRK and 99.5 for SOLV. Dividend yield: MRK 2.30%, SOLV none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$366B

    SOLV$15.5B

    MRK is 24 times SOLV

  • Revenue, 12 months

    MRK$67.4B

    SOLV$8.2B

    MRK is 8.3 times SOLV

  • Net income, 12 months

    MRK$2.5B

    SOLV$156M

    MRK is 16 times SOLV

  • Operating margin

    MRK–

    SOLV5.6%

  • ROIC

    MRK3.9%

    SOLV4.2%

    0.3 points apart

  • P/E

    MRK149.2

    SOLV99.5

    MRK is 1.5 times SOLV

  • Dividend yield

    MRK2.3%

    SOLV0.0%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+64.0%

SOLV+18.2%

100125150175DecFebAprJunAugOct
Returns by period
PeriodMRKWith dividendsSOLVWith dividends
1 year since November 14, 2025+64.0%Price +59.3%+18.3%Price +18.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanySOLVSolventum

Valuation

MRKSOLV
Valuation
Price$148.02$89.47
Market value$366B$15.5B
Enterprise value (EV)$410B$20.3B
P/E149.299.5
P/E, 5-year median14.8–
P/B8.23.2
EV/EBIT86.144.7
Free cash flow yield4.0%–

Results and growth

MRKSOLV
Results and growth
Revenue, 12 months$67.4B$8.2B
Net income, 12 months$2.5B$156M
Free cash flow, 12 months$14.7B$0
Earnings per share, 12 months$0.98$0.88
Revenue growth, year on year1.3%0.9%
Revenue growth a year, past+9.4%over 5 years+0.8%over 3 years
EPS growth a year, past+21.2%over 5 years+4.5%over 3 years

Margins and returns on capital

MRKSOLV
Margins and returns on capital
Gross margin71.8%54.8%
Operating margin–5.6%
Net margin3.6%1.9%
ROIC3.9%4.2%
ROE5.2%3.2%

Balance sheet

MRKSOLV
Balance sheet
Cash$9.7B$451M
Total debt$53.8B$5.3B
Net debt / EBITDA5.75.1
Interest cover2.4×–

Dividends and buybacks

MRKSOLV
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.4%–
Shareholder yield3.7%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or SOLV

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Solventum?

By market value, Merck & Company ($366B) is about 23.6 times Solventum ($15.5B), at today's prices.

How did MRK and SOLV stock do over the last 1 years?

Since November 14, 2025, MRK's price moved +59.3% and SOLV's +18.3%. With dividends: MRK +64.0% (+64.0% a year), SOLV +18.3% (+18.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or SOLV?

The dividend yield at today's price is 2.30% for Merck & Company and none for Solventum. Over the last twelve months they paid $3.40 and – per share.

What is the P/E of MRK and SOLV?

At today's price, the P/E is 149.2 for MRK and 99.5 for SOLV. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Merck & Company or Solventum?

Over the last twelve months, the net margin was 3.6% for Merck & Company and 1.9% for Solventum, and the operating margin – and 5.6%. Revenue was $67.4B and $8.2B.

Which is the better investment, Merck & Company or Solventum?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.